James E. Herndon

<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas

Hai Yan, D. Williams Parsons, Genglin Jin et al. · New England Journal of Medicine · 2009 · 5.9K citations · Full text

Medicine, Genetics, Oncology +16

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

James J. Vredenburgh, Annick Desjardins, James E. Herndon et al. · Journal of Clinical Oncology · 2007 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

James J. Vredenburgh, Annick Desjardins, James E. Herndon et al. · Clinical Cancer Research · 2007 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Gary M. Strauss, James E. Herndon, Michael A. Maddaus et al. · Journal of Clinical Oncology · 2008 · 990 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial

R O Dillman, James E. Herndon, Stephen L. Seagren et al. · JNCI Journal of the National Cancer Institute · 1996 · 932 citations · Full text

Medicine, Oncology, Radiation Oncology +11